title: Drug Development and Biologics in Asthma. A New Era.
abstract: Considerable progress has been made toward developing targeted biological therapeutics for asthma, due in large part to a deeper understanding of asthma pathophysiology. This explosion of knowledge has revealed asthma to be a much more complex and heterogeneous entity than previously understood. The identification of particular asthma phenotypes with distinct pathophysiologic mechanisms has opened up a new era for patient populations not well served by current therapies, especially patients with severe asthma.
authors.affiliation: Department of Medicine, University of California, San Francisco, and California Institute for Regenerative Medicine, San Francisco, California.
authors.forename: Ramona
authors.identifier: http://orcid.org/0000-0003-4506-6188
authors.initials: R
authors.lastname: Doyle
mesh_terms: D000818:Animals; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000178:diet therapy* / Q000188:drug therapy; D001688:Biological Products / Q000627:therapeutic use*; D055808:Drug Discovery / Q000379:methods*; D006801:Humans
chemical_list: D018927:Anti-Asthmatic Agents; D001688:Biological Products
keywords: asthma; biologics; clinical trials; drug development; omalizumab